- Home
- XNCR vs DEI Comparison
XNCR vs DEI Comparison
Compare XNCR & DEI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XNCR | DEI |
|---|---|---|
| Founded | 1997 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.9B |
| IPO Year | 2013 | 2006 |
Fundamental Metrics
Financial Performance| Metric | XNCR | DEI |
|---|---|---|
| Price | $24.77 | $9.71 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 14 | 12 |
| Target Price | ★ $31.42 | $13.10 |
| AVG Volume (30 Days) | 1.0M | ★ 1.8M |
| Earning Date | 11-04-2026 | 11-03-2026 |
| Dividend Yield | N/A | ★ 7.93% |
| EPS Growth | ★ 65.36 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $125,576,000.00 | ★ $1,003,982,000.00 |
| Revenue This Year | $14.05 | $1.74 |
| Revenue Next Year | N/A | $3.04 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 13.65 | 1.77 |
| 52 Week Low | $10.38 | $9.04 |
| 52 Week High | $30.61 | $15.83 |
Technical Indicators
Market Signals| Indicator | XNCR | DEI |
|---|---|---|
| Relative Strength Index (RSI) | 51.52 | 27.09 |
| Support Level | $23.36 | $9.53 |
| Resistance Level | $30.61 | $10.18 |
| Average True Range (ATR) | 1.03 | 0.28 |
| MACD | -0.09 | -0.05 |
| Stochastic Oscillator | 55.23 | 7.83 |
Price Performance
Historical ComparisonAbout XNCR Xencor Inc.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
About DEI Douglas Emmett Inc.
Douglas Emmett Inc is an integrated, self-administered, and self-managed REIT. The group focuses on owning, acquiring, developing, and managing a substantial market share of office properties and multifamily communities in neighborhoods with supply constraints, high-end executive housing, and key lifestyle amenities. Its properties are located in the Beverly Hills, Brentwood, Burbank, Century City, Olympic Corridor, Santa Monica, Sherman Oaks/Encino, Warner Center/Woodland Hills and Westwood submarkets of Los Angeles County, California, and in Honolulu, Hawaii. It has two business segments: the office segment and multifamily segment, of which Office segment derives maximum revenue.